Amneal Pharmaceuticals (AMRX) Revenue & Revenue Breakdown
Amneal Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$3.02B
Latest Revenue (Q)
$784.51M
Main Segment (Y)
Specialty Segment
Main Geography (Y)
Specialty Segment
Amneal Pharmaceuticals Revenue by Period
Amneal Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $3.02B | 8.05% |
| 2024-12-31 | $2.79B | 16.73% |
| 2023-12-31 | $2.39B | 8.20% |
| 2022-12-31 | $2.21B | 5.67% |
| 2021-12-31 | $2.09B | 5.08% |
| 2020-12-31 | $1.99B | 22.51% |
| 2019-12-31 | $1.63B | -2.20% |
| 2018-12-31 | $1.66B | 60.88% |
| 2017-12-31 | $1.03B | 1.52% |
| 2016-12-31 | $1.02B | 17.54% |
| 2015-12-31 | $866.28M | 10.27% |
| 2014-12-31 | $785.62M | - |
Amneal Pharmaceuticals generated $3.02B in revenue during NA 2025, up 8.05% compared to the previous quarter, and up 151.50% compared to the same period a year ago.
Amneal Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $784.51M | 8.28% |
| 2025-06-30 | $724.51M | 4.18% |
| 2025-03-31 | $695.42M | -4.80% |
| 2024-12-31 | $730.52M | 3.99% |
| 2024-09-30 | $702.47M | 0.10% |
| 2024-06-30 | $701.78M | 6.46% |
| 2024-03-31 | $659.19M | 6.84% |
| 2023-12-31 | $616.98M | -0.49% |
| 2023-09-30 | $620.04M | 3.50% |
| 2023-06-30 | $599.05M | 7.44% |
| 2023-03-31 | $557.54M | -8.56% |
| 2022-12-31 | $609.76M | 11.77% |
| 2022-09-30 | $545.56M | -2.47% |
| 2022-06-30 | $559.36M | 12.40% |
| 2022-03-31 | $497.63M | -7.31% |
| 2021-12-31 | $536.90M | 1.57% |
| 2021-09-30 | $528.59M | -1.21% |
| 2021-06-30 | $535.08M | 8.51% |
| 2021-03-31 | $493.11M | -3.32% |
| 2020-12-31 | $510.03M | -1.78% |
| 2020-09-30 | $519.29M | 11.76% |
| 2020-06-30 | $464.66M | -6.79% |
| 2020-03-31 | $498.53M | 25.47% |
| 2019-12-31 | $397.33M | 5.03% |
| 2019-09-30 | $378.28M | -6.51% |
| 2019-06-30 | $404.64M | -9.30% |
| 2019-03-31 | $446.12M | -10.33% |
| 2018-12-31 | $497.53M | 4.42% |
| 2018-09-30 | $476.49M | 15.15% |
| 2018-06-30 | $413.79M | 50.36% |
| 2018-03-31 | $275.19M | -6.20% |
| 2017-12-31 | $293.37M | 15.17% |
| 2017-09-30 | $254.73M | -1.98% |
| 2017-06-30 | $259.87M | 15.15% |
| 2017-03-31 | $225.68M | -24.41% |
| 2016-12-31 | $298.58M | - |
Amneal Pharmaceuticals generated $784.51M in revenue during Q3 2025, up 8.28% compared to the previous quarter, and up 111.79% compared to the same period a year ago.
Amneal Pharmaceuticals Revenue Breakdown
Amneal Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Specialty Segment | $528.51M | $445.75M | $390.46M | - | - |
| Generics Segment | - | - | $1.47B | $1.43B | $1.37B |
| Av K A R E Segment | - | - | - | $406.11M | - |
| Amneal Specialty Pharma Segment | - | - | - | $374.12M | $378.32M |
| Av Kare | - | - | - | - | $349.01M |
Amneal Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Specialty Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Segment | $420.21M | $108.30M | $88.64M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Amneal Specialty Pharma Segment | - | $125.24M | $128.04M | $108.30M | $115.64M | $105.23M | $96.99M | $91.68M | $102.55M | $89.48M | $97.00M | $85.09M | $101.01M | $92.75M | $95.93M | $85.47M | $87.87M | $94.26M | - | - |
| Generics Segment | - | - | - | - | $427.35M | $391.29M | $753.89M | $373.70M | $343.81M | $399.17M | $350.27M | $364.89M | $317.75M | $346.27M | $347.13M | $360.44M | $312.51M | $342.14M | $341.92M | $306.56M |
| Av K A R E Segment | - | - | - | - | - | - | - | $128.35M | $122.06M | $108.04M | $105.81M | $97.46M | $94.80M | $88.72M | $86.00M | $84.67M | $89.51M | $63.85M | - | - |
Amneal Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Specialty Segment (100.00%).
Amneal Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Specialty Segment | $528.51M | $445.75M | $390.46M | $374.12M | $378.32M |
| Generics Segment | - | - | $1.47B | $41.09M | $35.97M |
Amneal Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: Specialty Segment (100.00%).
Quarterly Revenue by Country
| Country | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Segment | $275.23M | $125.24M | $128.04M | $108.30M | $224.88M | $115.64M | $105.23M | $201.78M | $96.99M | $91.68M | $102.55M | $89.48M | $97.00M | $85.09M | $101.01M | $92.75M | $88.64M | $95.93M | $85.47M | $87.87M |
| Generics Segment | - | - | - | - | - | $427.35M | $391.29M | $1.45B | $11.14M | $12.81M | $14.58M | $8.72M | $12.12M | $5.67M | $9.09M | $8.23M | $10.46M | $8.18M | $9.19M | $10.88M |
Amneal Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 25: Specialty Segment (100.00%).
Amneal Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BHC | Bausch Health Companies | $10.16B | $912.00M |
| PRGO | Perrigo | $4.25B | $1.04B |
| AMRX | Amneal Pharmaceuticals | $3.02B | $784.51M |
| NVST | Envista | $2.72B | $669.90M |
| LNTH | Lantheus | $1.54B | $384.01M |
| TLX | Telix Pharmaceuticals | $783.21M | $7.41M |
| SUPN | Supernus Pharmaceuticals | $718.95M | $192.10B |
| MIRM | Mirum Pharmaceuticals | $521.31M | $133.01M |
| SLNO | Soleno Therapeutics | $190.41M | $66.02M |
| DYN | Dyne Therapeutics | - | - |